Aurora Cannabis (TSX:ACB)(NASDAQ: ACB), a leading international cannabis producer, recently posted its third-quarter results for fiscal year 2024. It also announced the acquisition of MedReleaf Australia as it looks to grow its position in international cannabis markets. Is the stock on the right path to turning things around?
Aurora reported a net revenue increase to $64.4 million in Q3 2024, higher than the $61.1 million it posted in the prior-year period. The growth was primarily due to a stronger performance in its global medical marijuana business.
The company also showed improvement on the bottom line, with adjusted EBITDA of $4.3 million coming in higher than what it reported…
